A synthetic α-MSH analog that activates three melanocortin receptor subtypes — the original tanning peptide that inadvertently became the foundation for PT-141's FDA approval.
Melanotan II (MT-II) is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), engineered to be more potent and metabolically stable than the naturally occurring peptide. It was developed at the University of Arizona in the 1980s as part of a program to create a sunless tanning agent that could protect against UV-induced skin damage.
The peptide activates multiple melanocortin receptors — primarily MC1R (pigmentation), MC3R and MC4R (appetite and sexual function). This broad receptor profile is why MT-II research spans three seemingly unrelated areas: skin pigmentation, libido, and appetite suppression. It's the same compound doing all three things through different receptor subtypes.
Melanotan II has never received regulatory approval. Its broader receptor activity compared to the more selective PT-141 (which targets MC3R/MC4R specifically) is both the source of its wider effects and the reason it carries a more complex side effect profile. PT-141 (bremelanotide) was derived from MT-II research and received FDA approval in 2019 — MT-II itself did not.
MT-II is a non-selective melanocortin receptor agonist. Its cyclic structure makes it resistant to enzymatic degradation compared to linear α-MSH, and its potency at melanocortin receptors is significantly higher than the endogenous peptide. The three primary research applications map to three different receptor subtypes:
MC1R activation on melanocytes stimulates eumelanin (brown/black pigment) production. Eumelanin provides photoprotection — it absorbs UV radiation more effectively than phaeomelanin (the red/yellow pigment associated with fair skin). MT-II research originally aimed to induce this pigmentation response systemically, producing a tan-like photoprotective state without UV exposure.
MC4R in particular is expressed in the hypothalamus and limbic system, where melanocortin signaling modulates sexual arousal circuits. MT-II activation of MC4R produces penile erection in male animal models and increased sexual receptivity in female models through central nervous system pathways — independent of sex hormones. This observation directly led to the development of PT-141 (bremelanotide), which selectively targets these receptors.
MC4R in the hypothalamic arcuate nucleus plays a key role in energy homeostasis. Activation suppresses appetite and increases energy expenditure — a mechanism central to the obesity pharmacology literature. This is why MT-II research overlaps with metabolic applications.
The melanocortin system is ancient and broadly distributed — it evolved to coordinate multiple physiological responses (stress, inflammation, reproduction, energy balance, pigmentation) through a single signaling system. MT-II's non-selective agonism activates this entire system, producing effects across all the tissues that express melanocortin receptors.
PT-141 (bremelanotide) was developed directly from Melanotan II research. The University of Arizona team observed the sexual function effects of MT-II in clinical subjects and pursued a more selective analog focused specifically on those effects. The result was PT-141 — cyclic melanocortin analog without the tanning effect, FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
| Factor | Melanotan II | PT-141 (Bremelanotide) |
|---|---|---|
| Receptor selectivity | MC1R, MC3R, MC4R (non-selective) | MC3R, MC4R (more selective) |
| Tanning effect | Yes — MC1R activation | Minimal |
| Sexual function effect | Yes — MC4R | Yes — primary application |
| Appetite suppression | Yes — MC4R | Some, less pronounced |
| FDA approval | None | Approved 2019 (Vyleesi) |
| Nausea risk | Higher (broader receptor activation) | Present but better characterized |
| Research dose (SubQ) | 500mcg – 1mg | 1.75mg (FDA approved dose) |
COA-verified vendor pricing with promo codes. Tegridy Research currently carries Melanotan II.
View Pricing → Dosage Calculator